A capsid is the protein shell that surrounds and protects a virus’s genetic material. The word comes from the Latin “capsa,” meaning box, and that’s essentially what it is: a nanoscale container built from protein subunits that shields fragile DNA or RNA from the environment. Capsids do more than just protect, though. They also help viruses latch onto host cells, penetrate them, and deliver their genetic payload to start an infection.
What a Capsid Actually Does
A virus outside of a cell is just a packet of genetic material drifting through a hostile environment. Enzymes, UV light, temperature shifts, and pH changes can all destroy exposed DNA or RNA. The capsid’s first job is to keep that genetic cargo intact during transit from one host cell to the next.
But protection is only part of the story. The capsid’s outer surface carries proteins that recognize and bind to specific receptor molecules on the surface of a host cell. This binding is highly selective. A virus that infects dogs, for example, has capsid surface features that fit receptors on canine cells, and even small changes to those surface proteins can shift which species or cell types the virus can infect. Once the capsid locks onto the right receptor, it triggers a process that allows the virus to penetrate the cell membrane and release its genome inside.
So the capsid serves three core functions: protect the genome, transport it between hosts, and deliver it into a new cell.
How Capsids Are Built
Capsids aren’t manufactured as a single piece. They self-assemble from smaller protein building blocks called capsomeres, which are themselves made of even smaller protein units called protomers. During an active infection, the host cell’s own machinery is hijacked to produce these protein subunits continuously. The capsomeres then snap together through chemical interactions, forming the finished shell without any external template or guide. It’s one of the more remarkable examples of self-assembly in biology.
Once assembled, a capsid can be extraordinarily sturdy for its size. Some capsids withstand internal pressures comparable to those inside a champagne bottle, which is necessary because tightly packed DNA inside the shell pushes outward with significant force.
Three Main Capsid Shapes
Viruses come in a surprising variety of forms, but their capsids generally follow one of three geometric patterns.
Icosahedral capsids are roughly spherical, built from 20 triangular faces arranged into a shape that resembles a soccer ball. This is the most efficient way to enclose a maximum volume with the fewest protein subunits, and it’s extremely common. Viruses that cause the common cold (adenoviruses), polio, and hepatitis A all use icosahedral capsids. Most range from about 20 to 300 nanometers across, far too small to see with an ordinary microscope.
Helical capsids form long tubes or rods. The protein subunits wind around the nucleic acid in a spiral, like steps on a spiral staircase. Tobacco mosaic virus is the classic example, and the viruses that cause rabies, Ebola, and influenza also have helical nucleocapsids (though influenza and Ebola wrap theirs in an additional outer envelope).
Complex capsids don’t fit neatly into either category. The best-known example is bacteriophage T4, a virus that infects bacteria. T4 looks almost like a lunar lander: it has an elongated icosahedral head (about 115 nanometers long) that holds its DNA, a 92.5-nanometer contractile tail, a hexagonal baseplate at the bottom, and six long tail fibers that act as sensors to find the right bacterial host. When the tail fibers detect a target, the baseplate changes shape from a dome to a star, the tail sheath contracts, and the inner tail tube essentially drills through the bacterial membrane to inject the genome.
Capsid vs. Nucleocapsid
You’ll sometimes see these two terms used interchangeably, but they refer to slightly different things. The capsid is the protein shell alone. The nucleocapsid is the capsid plus the genetic material inside it. In helical viruses, the distinction gets blurry because the capsid proteins wind directly around the nucleic acid, so the two components are physically intertwined. In icosahedral viruses, the shell is more clearly separate from the genome it contains.
Enveloped vs. Naked Capsids
Some viruses wrap their capsid in an additional outer layer, a lipid membrane studded with proteins, called an envelope. Influenza, HIV, and coronaviruses all have envelopes. Others, like norovirus and poliovirus, go without. These “naked” viruses present only the bare capsid to the outside world.
This distinction has real practical consequences. Non-enveloped viruses are generally tougher. They survive longer on surfaces, resist drying, and persist in water and food. That’s why norovirus spreads so effectively through contaminated food and why it’s notoriously hard to kill with hand sanitizer (alcohol disrupts lipid envelopes but has less effect on a bare protein shell). Enveloped viruses, by contrast, tend to be more fragile outside the body but have their own advantages: the envelope helps them slip past certain immune defenses, and the surface proteins embedded in it can be highly effective at binding host cells.
Humidity plays a role too. Enveloped viruses generally remain viable longer in dry air (20 to 30% relative humidity), while non-enveloped viruses tend to survive better in humid conditions (70 to 90%).
How Capsids Start an Infection
Infection begins when proteins on the capsid’s outer surface recognize and bind to a specific receptor on a host cell. This interaction is often compared to a lock and key: the virus can only infect cells that display the right receptor. Research on canine parvovirus, for instance, shows that the virus binds to a receptor called transferrin receptor on the cell surface, using small protruding “spikes” near specific axes of the capsid. The residues on these spikes determine whether the virus can infect canine cells, feline cells, or both.
What happens next depends on the virus. For non-enveloped viruses, binding to the receptor can trigger a shape change in the capsid that allows the genetic material to pass through or destabilize the cell membrane. For bacteriophages like T4, it’s more dramatic: the tail contracts and physically punches through the bacterial wall. In either case, the capsid’s job is to get the genome from outside the cell to inside, intact and ready to hijack the cell’s machinery.
Interestingly, the initial binding event breaks the capsid’s symmetry. An icosahedral capsid has 60 identical binding sites, but when the virus first contacts a cell membrane, only one or a few of those sites actually engage a receptor. This asymmetric attachment may help trigger the structural changes the virus needs to penetrate the cell.
Capsids in Gene Therapy
The same properties that make capsids effective at delivering viral genomes into cells have made them valuable tools in medicine. Scientists now engineer capsids, particularly from adeno-associated viruses (AAV), to deliver therapeutic genes instead of viral ones. AAVs are attractive because they don’t cause disease, and they’ve been modified so their DNA cargo doesn’t permanently insert into the patient’s genome. Instead, the therapeutic gene sits outside the chromosomes and directs production of a needed protein.
The engineering challenge is precision. A natural AAV capsid might enter many different cell types, but a gene therapy for a liver disease needs the capsid to target liver cells specifically, without entering cells in the brain, heart, or kidneys. Researchers at Harvard’s Wyss Institute have mapped which regions of the AAV capsid can be modified without compromising its structural integrity. The core of the capsid is inflexible: change it and the shell falls apart. But the protruding spikes that bind to cell receptors are surprisingly tunable.
Using machine learning, researchers have generated thousands of capsid variants with altered surface proteins, then tested which ones home in on specific tissues. A collaboration with Google Research developed an AI-driven approach called “Deep Search” that identifies combinations of mutations improving both cell-targeting specificity and the ability to evade the immune system. This matters because many people carry antibodies against natural AAV from prior exposure, which can neutralize the therapy before it reaches its target. Synthetic capsids designed to dodge those antibodies could make gene therapy effective for a much larger patient population.